Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0021311 (Infection)
 38,178 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effect of pretransplantation hemoglobin (Hb) concentration on the outcome of kidney transplantation (KTx) was studied in 188 adult kidney transplant recipients. Patients were divided into 2 groups: high Hb (>or=10 g/dL; n=97) and low Hb (<10 g/dL; n=91). Both groups were matched for recipient sex, donor age and sex, donor-recipient blood groups, indications for kidney transplantation, and degree of sensitization. Acute rejection episodes occurred in 20 patients in the high-Hb group (20.6%) and 18 in the low-Hb group (19.8%). Antithymocyte globulin-Fresenius therapy was required in 6 patients in the high-Hb group compared with 5 patients in the low-Hb group. Infection rate, 1-year actuarial patient and graft survival, incidence of delayed and slow graft function, and number of surgical complications were comparable between groups. Compared with the low Hb group, in the high-Hb group, hospital stay was longer, creatinine concentration at 12 months post-KTx and serum glucose concentration at 6 months post-KTx were significantly higher, and pre- and posttransplantation Hb concentrations were higher. The need for post-KTx transfusions was comparable between groups. Pretransplantation Hb concentration did not affect outcome except for longer initial hospital stay and 1-year creatinine concentration.
 ...
PMID:Effect of pretransplantation hemoglobin blood concentration on renal allograft survival and function. 2415 30

Haploidentical hematopoietic stem cell transplantation (haploHSCT) with conditioning regimens using post-transplant cyclophosphamide (PTCy) for peripheral blood stem cell (PBSC) grafts is limited by comparably higher rates of acute and chronic graft-versus-host disease (GVHD). Antithymocyte globulin (ATG) may mitigate this risk. We evaluated haploHSCT after reduced-intensity conditioning (RIC) with ATG, PTCy, and cyclosporine to prevent rejection and GVHD. Fifty adults underwent haploHSCT from August 2016 to February 2018. RIC included fludarabine (30 mg/m2/day on days -5 to -2), busulfan (3.2 mg/m2/day on days -3 and -2), and total body irradiation (200 cGy) on day -1. Unmanipulated PBSCs were infused on day 0. GVHD prophylaxis included ATG (4.5 mg/kg over days -3 to -1), PTCy (50 mg/kg/day on days +3 and +4), and cyclosporine from day +5. Median age was 56 years (range, 22 to 70 years); 25 (73.5%) patients were in first complete remission (CR1), 5 (14.7%) were in second complete remission (CR2), and 8 (23.5%) had active disease. Median time to neutrophil engraftment was 16 days (range, 8 to 43 days). At day +100, the cumulative incidence of acute GVHD of any grade, and grades III to IV was 38.3% and 5.2%, respectively. Mild chronic GVHD was seen in 15.5%. Cytomegalovirus (CMV) reactivation occurred in 37 (74%) cases and CMV disease occurred in 4 (11.5%) cases. Epstein-Barr virus (EBV) reactivation occurred in 21 (61.8%) patients. The incidence of histologically confirmed post-transplantation lymphoproliferative disorder (PTLD) was 5.8%. Four patients received rituximab. There were no CMV, EBV, or PTLD-related deaths. Six-month and 1-year overall survival (OS), cumulative incidence of relapse (CIR), and nonrelapse mortality (NRM) were 73.9%, 10.2%, and 19.4%, respectively, and 48.1%, 16% and 38.2%, respectively. Infection was the most common cause of death (18%). Unmanipulated haploidentical PBSC transplantation following RIC with ATG, PTCy, and cyclosporine as a GVHD prevention strategy results in low rates of acute and chronic GVHD.
 ...
PMID:Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies. 3000 80